Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K. Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905). J Thorac Oncol. 2017;12(8):1299–308.

Article  Google Scholar 

Hwang KE, Kim YS, Jung JW, Kwon SJ, Park DS, Cha BK, Oh SH, Yoon KH, Jeong ET, Kim HR. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells. Oncotarget. 2015;6(30):29482–96.

Article  Google Scholar 

Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L. Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs. 2009;14(3):423–37.

CAS  Article  Google Scholar 

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P. Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial. J Clin Oncol. 2017;35(31):3591–600.

CAS  Article  Google Scholar 

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14.

CAS  Article  Google Scholar 

Curtin N, Hughes A. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet. 2001;2(5):298–306.

CAS  Article  Google Scholar 

Remon J, Nadal E, Domine M, Ruffinelli J, Garcia Y, Pardo JC, Lopez R, Cilleruelo A, Garcia-Campelo R, Martin P, Juan O, Gonzalez-Larriba JL, Provencio M, Olmedo E, Ponce S, Cumplido D, Barenys C, Majem M, Massutti B, Rodriguez-Abreu D, Porta R, Sala MA, Martinez-Kareaga M, Lianes P, Reguart N. Malignant pleural mesothelioma: treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020;147:83–90.

CAS  Article  Google Scholar 

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC-H, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet. 2016;17(11):1497–1508.

Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu Y-L, Bover I, Begbie S, Tzekova V. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–40.

CAS  Article  Google Scholar 

Glezerman IG, Pietanza MC, Miller V, Seshan SV. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011;58(5):817–20.

CAS  Article  Google Scholar 

Boosman RJ, Dorlo TPC, de Rouw N, Burgers JA, Dingemans AC, van den Heuvel MM, Hendriks LEL, Biesma B, Aerts J, Croes S, Mathijssen RHJ, Huitema ADR, Ter Heine R. Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment. Int J Cancer. 2021;149:1576–84.

CAS  Article  Google Scholar 

Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10(3):721–5.

Article  Google Scholar 

Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.

CAS  Article  Google Scholar 

Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, Mrakic-Sposta S, Moretti S, Monti M, Pignochino Y, Benvenuti S, Prosperi D, Stella G, Morbini P, Meloni F. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study. Int J Nanomedicine. 2019;14:773–85.

CAS  Article  Google Scholar 

Yang W, Yang L, Xia Y, Cheng L, Zhang J, Meng F, Yuan J, Zhong Z. Lung cancer specific and reduction-responsive chimaeric polymersomes for highly efficient loading of pemetrexed and targeted suppression of lung tumor in vivo. Acta Biomater. 2018;70:177–85.

CAS  Article  Google Scholar 

Lu N, Li R, Liu Q, Hu B, Xu X, Ji C, Han X, Wang P, Liu B. Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B16 bearing mice. Drug Deliv. 2016;23(7):2566–74.

CAS  Article  Google Scholar 

Amano Y, Ohta S, Sakura KL, Ito T. Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma. Eur J Pharm Sci. 2019;138:105008.

Li T, Pan S, Gao S, Xiang W, Sun C, Cao W, Xu H. Diselenide-pemetrexed assemblies for combined cancer immuno-, radio-, and chemotherapies. Angew Chem Int Ed Engl. 2020;59(7):2700–4.

CAS  Article  Google Scholar 

Xu L, Yu C, Wang D, Pang J, Shi L, Su Y, Gong L, Yan D, Zhu X. Endogenous nucleotide as drug carrier: base-paired guanosine-5′-monophosphate:pemetrexed vesicles with enhanced anticancer capability. Sci China Chem. 2019;63(2):244–53.

Article  Google Scholar 

Ando H, Kobayashi S, Abu Lila AS, Eldin NE, Kato C, Shimizu T, Ukawa M, Kawazoe K, Ishida T. Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed. J Control Release. 2015;220(Pt A):29–36.

CAS  Article  Google Scholar 

Mondal G, Kumar V, Shukla SK, Singh PK, Mahato RI. EGFR-targeted polymeric mixed micelles carrying gemcitabine for treating pancreatic cancer. Biomacromol. 2016;17(1):301–13.

CAS  Article  Google Scholar 

Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006;51(2):207–15.

Dazzi H, Hasleton P, Thatcher N, Wilkes S, Swindell R, Chatterjee A. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer. 1990;61:924–926.

Chia PL, Scott AM, John T. Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma. Expert Opin Drug Deliv. 2019;16(4):441–51.

CAS  Article  Google Scholar 

Genta I, Chiesa E, Colzani B, Modena T, Conti B, Dorati R. GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview. Pharmaceutics. 2017;10(1):2.

Article  Google Scholar 

Pi J, Jiang J, Cai H, Yang F, Jin H, Yang P, Cai J, Chen ZW. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways. Drug Deliv. 2017;24(1):1549–64.

CAS  Article  Google Scholar 

Lee D, Lee YM, Kim J, Lee MK, Kim WJ. Enhanced tumor-targeted gene delivery by bioreducible polyethylenimine tethering EGFR divalent ligands. Biomater Sci. 2015;3(7):1096–104.

CAS  Article  Google Scholar 

Fang Y, Yang W, Cheng L, Meng F, Zhang J, Zhong Z. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Acta Biomater. 2017;64:323–33.

CAS  Article  Google Scholar 

Yao P, Zhang Y, Meng H, Sun H, Zhong Z. Smart polymersomes dually functionalized with cRGD and fusogenic GALA peptides enable specific and high-efficiency cytosolic delivery of apoptotic proteins. Biomacromol. 2019;20(1):184–91.

CAS  Article  Google Scholar 

Zhong Y, Meng F, Zhang W, Li B, van Hest JCM, Zhong Z. CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice. J Control Release. 2020;320:421–30.

CAS  Article  Google Scholar 

Mezzapelle R, Miglio U, Rena O, Paganotti A, Allegrini S, Antona J, Molinari F, Frattini M, Monga G, Alabiso O. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. Br J Cancer. 2013;108(8):1743–9.

CAS  Article  Google Scholar 

Destro A, Ceresoli G, Falleni M, Zucali P, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M. EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006;51(2):207–15.

CAS  Article  Google Scholar 

Enomoto Y, Kasai T, Takeda M, Takano M, Morita K, Kadota E, Iizuka N, Maruyama H, Haratake J, Kojima Y. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma. J Clin Pathol. 2012;65(6):522–7.

CAS  Article  Google Scholar 

Liang J, Lu T, Chen Z, Zhan C, Wang Q. Mechanisms of resistance to pemetrexed in non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(6):1107–18.

CAS  Article  Google Scholar 

Buqué A, Muhialdin JS, MuñOz A, Calvo B, Carrera S, Aresti U, Sancho A, Rubio I, López-Vivanco G. Molecular mechanism implicated in pemetrexed-induced apoptosis in human melanoma cells. Mol Cancer. 2012;11:25.

Article  Google Scholar